Comparison of Financial and Operating Conditions of Companies in The Biomedical Industry Before and after COVID-19

Authors

  • Mingshan Xia
  • Boqian Zhan
  • Hanchu Zhan

DOI:

https://doi.org/10.54691/bcpbm.v37i.3577

Keywords:

Corporate finance; State of Operation; Biological Medicine industries; COVID-19.

Abstract

The outbreak of COVID-19 has brought various influences to the Biological Medicine industries. any biomedical companies have been fighting on the front lines from beginning to end. This essay uses Mingde Biotechnology Company as the classical case to analyze and compare the Biological Medicine industry’s corporate finance and state of operation before and after COVID-19. Through research, Mingde Biotechnology Company experienced a dramatic profit. Therefore, the conclusion is that COVID-19 gives additional benefits to Biological Medicine industries due to the increasing demand for Nucleic acid tests and some other medical supplies. Nevertheless, because of the wane of the pandemic, the demand for the Nucleic acid test which is also the main business of the Biological Medicine industry, so the meaning of the research is to give more ways for this enterprise to continue to gain profits in the post-pandemic era. Companies benefiting from the epidemic should take advantage of this opportunity to develop more cutting-edge medical products, realize domestic substitution, and better serve the people.

Downloads

Download data is not yet available.

References

Yao L L. (2020). Chen L L. Mingde Biology pays attention to symbiosis. Person of outstanding ability (Z2), 35.

Zhu L. (2013). Yu Mingde: Innovation and development of biomedical industry. China Science and Technology Investment (13),23-25

Chen Lixiang (2022-07-25). Mingde Biology: A new star of IVD comprehensive service for successful doctors' entrepreneurship. Securities Times, A04

Zhu Ziheng. (2016). Investment Value Analysis of Mingde Biology (430591) (Master's Thesis, Lanzhou University).

Wu L. (2022). The performance of Mingde Biological Industry soared. Supporting point (6), 64-65.

Cao Wei, & Zhang Honghua. (2018). Mingde Biology: a high-quality "dark horse" in the medical field. Hubei Pictorial News (early).

Wang Dongmei, Zhang Zhihong, & Gao Fei. (2018). A case study of NEEQ enterprise valuation: A Case study of Mingde Biologics. China Asset Appraisal, (1), 50-56.

Hu Haipeng & Yuan Yong. (2022). Theoretical research on promoting innovation and development of biomedical industry. Decision Consulting (04),62-67.

Sun XR. (2022). Development trend and opportunity analysis of biomedical industry. China's national power (08), 25 to 29. Doi: 10.13561 / j. carol carroll nki ZGGQGL. 2022.08.007.

Li Haitian & Li Xiang. (2022). Study on the model of industry-university-research cooperation in China's biomedical industry. Science and Technology and Industry (07),57-62.

Downloads

Published

2023-02-01

How to Cite

Xia, M., Zhan, B., & Zhan, H. (2023). Comparison of Financial and Operating Conditions of Companies in The Biomedical Industry Before and after COVID-19. BCP Business & Management, 37, 281-289. https://doi.org/10.54691/bcpbm.v37i.3577